COVID-19 response: Vaccines and therapeutics

 

Vaccines and therapeutics

In an effort to slow and eventually stop the spread of the virus, the NRC is working with partners to advance research and technology development for therapies and vaccines to treat and prevent COVID-19.

Quest for a vaccine: NRC researchers mobilize to advance technologies against COVID-19

As the global pandemic continues, scientists around the world are working at breakneck speed in an effort to develop safe and effective vaccine candidates against COVID-19.

Learn more about Quest for a vaccine: NRC researchers mobilize to advance technologies against COVID-19

Nanotechnology Research Centre joins COVID-19 Consortium

The NRC has joined a consortium of institutions that are merging supercomputing resources to use high-end computing power to study COVID-19.

Learn more about Nanotechnology Research Centre joins COVID-19 Consortium

NRC's publication on COVID-19 garners worldwide attention

Experts at the Nanotechnology and Human Health Therapeutics research centres recently published a highly consulted article on the impact that the SARS-CoV-2 infection has on the central nervous system (CNS).

Learn more about NRC's publication on COVID-19 garners worldwide attention

Funding domestic vaccine candidates as part of the GoC's COVID-19 response

On October 23, 2020, the Prime Minister announced an investment of over $23 million through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support Canadian companies responding to COVID- 19.

Learn more about Funding domestic vaccine candidates as part of the GoC's COVID-19 response

New made-in-Canada research tool in the fight against COVID-19

The NRC's spike protein reference material is now available for the Canadian research community. This high-quality spike protein antigen can be used for COVID-19 R&D, testing and vaccine development.

Learn more about the new made-in-Canada research tool in the fight against COVID-19